Synthesis, anti-HIV activity, and resistance profiles of ribose modified nucleoside phosphonates. 2007

Richard L Mackman, and Constantine G Boojamra, and Vidya Prasad, and Lijun Zhang, and Kuei-Ying Lin, and Oleg Petrakovsky, and Darius Babusis, and James Chen, and Janet Douglas, and Deborah Grant, and Hon C Hui, and Choung U Kim, and David Y Markevitch, and Jennifer Vela, and Adrian Ray, and Tomas Cihlar
Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA. rmackman@gilead.com

A series of nucleoside phosphonate reverse transcriptase (RT) inhibitors have been synthesized and their anti-HIV activity and resistance profiles evaluated. The most potent analog [5-(6-amino-purin-9-yl)-2,5-dihydro-furan-2-yloxymethyl]-phosphonic acid (d4AP) demonstrated a HIV EC(50)=2.1 microM, and the most favorable resistance profile against HIV-1 variants with K65R, M184V or multiple thymidine analog mutations in RT.

UI MeSH Term Description Entries
D009705 Nucleosides Purine or pyrimidine bases attached to a ribose or deoxyribose. (From King & Stansfield, A Dictionary of Genetics, 4th ed) Nucleoside,Nucleoside Analog,Nucleoside Analogs,Analog, Nucleoside,Analogs, Nucleoside
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D000068698 Tenofovir An adenine analog REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone. (R)-9-(2-phosphonylmethoxypropyl)adenine,9-(2-Phosphonomethoxypropyl)adenine,9-(2-Phosphonylmethoxypropyl)adenine,9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer,9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098,9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer,9-PMPA (tenofovir),Tenofovir Disoproxil,Tenofovir Disoproxil Fumarate,Viread,Disoproxil Fumarate, Tenofovir,Disoproxil, Tenofovir,Fumarate, Tenofovir Disoproxil
D000225 Adenine A purine base and a fundamental unit of ADENINE NUCLEOTIDES. Vitamin B 4,4, Vitamin B,B 4, Vitamin
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV
D020650 Combinatorial Chemistry Techniques A technology, in which sets of reactions for solution or solid-phase synthesis, is used to create molecular libraries for analysis of compounds on a large scale. Chemistry Techniques, Combinatorial,Techniques, Combinatorial Chemistry,Chemistry Technic, Combinatorial,Chemistry Technics, Combinatorial,Chemistry Technique, Combinatorial,Combinatorial Chemistry Technic,Combinatorial Chemistry Technics,Combinatorial Chemistry Technique,Technic, Combinatorial Chemistry,Technics, Combinatorial Chemistry,Technique, Combinatorial Chemistry

Related Publications

Richard L Mackman, and Constantine G Boojamra, and Vidya Prasad, and Lijun Zhang, and Kuei-Ying Lin, and Oleg Petrakovsky, and Darius Babusis, and James Chen, and Janet Douglas, and Deborah Grant, and Hon C Hui, and Choung U Kim, and David Y Markevitch, and Jennifer Vela, and Adrian Ray, and Tomas Cihlar
May 2009, Bioorganic & medicinal chemistry,
Richard L Mackman, and Constantine G Boojamra, and Vidya Prasad, and Lijun Zhang, and Kuei-Ying Lin, and Oleg Petrakovsky, and Darius Babusis, and James Chen, and Janet Douglas, and Deborah Grant, and Hon C Hui, and Choung U Kim, and David Y Markevitch, and Jennifer Vela, and Adrian Ray, and Tomas Cihlar
March 2006, Bioorganic & medicinal chemistry,
Richard L Mackman, and Constantine G Boojamra, and Vidya Prasad, and Lijun Zhang, and Kuei-Ying Lin, and Oleg Petrakovsky, and Darius Babusis, and James Chen, and Janet Douglas, and Deborah Grant, and Hon C Hui, and Choung U Kim, and David Y Markevitch, and Jennifer Vela, and Adrian Ray, and Tomas Cihlar
February 2019, Chemistry & biodiversity,
Richard L Mackman, and Constantine G Boojamra, and Vidya Prasad, and Lijun Zhang, and Kuei-Ying Lin, and Oleg Petrakovsky, and Darius Babusis, and James Chen, and Janet Douglas, and Deborah Grant, and Hon C Hui, and Choung U Kim, and David Y Markevitch, and Jennifer Vela, and Adrian Ray, and Tomas Cihlar
April 2018, European journal of medicinal chemistry,
Richard L Mackman, and Constantine G Boojamra, and Vidya Prasad, and Lijun Zhang, and Kuei-Ying Lin, and Oleg Petrakovsky, and Darius Babusis, and James Chen, and Janet Douglas, and Deborah Grant, and Hon C Hui, and Choung U Kim, and David Y Markevitch, and Jennifer Vela, and Adrian Ray, and Tomas Cihlar
July 2017, Organic & biomolecular chemistry,
Richard L Mackman, and Constantine G Boojamra, and Vidya Prasad, and Lijun Zhang, and Kuei-Ying Lin, and Oleg Petrakovsky, and Darius Babusis, and James Chen, and Janet Douglas, and Deborah Grant, and Hon C Hui, and Choung U Kim, and David Y Markevitch, and Jennifer Vela, and Adrian Ray, and Tomas Cihlar
October 2011, Journal of medicinal chemistry,
Richard L Mackman, and Constantine G Boojamra, and Vidya Prasad, and Lijun Zhang, and Kuei-Ying Lin, and Oleg Petrakovsky, and Darius Babusis, and James Chen, and Janet Douglas, and Deborah Grant, and Hon C Hui, and Choung U Kim, and David Y Markevitch, and Jennifer Vela, and Adrian Ray, and Tomas Cihlar
October 2005, Current protocols in nucleic acid chemistry,
Richard L Mackman, and Constantine G Boojamra, and Vidya Prasad, and Lijun Zhang, and Kuei-Ying Lin, and Oleg Petrakovsky, and Darius Babusis, and James Chen, and Janet Douglas, and Deborah Grant, and Hon C Hui, and Choung U Kim, and David Y Markevitch, and Jennifer Vela, and Adrian Ray, and Tomas Cihlar
January 1999, Nucleic acids symposium series,
Richard L Mackman, and Constantine G Boojamra, and Vidya Prasad, and Lijun Zhang, and Kuei-Ying Lin, and Oleg Petrakovsky, and Darius Babusis, and James Chen, and Janet Douglas, and Deborah Grant, and Hon C Hui, and Choung U Kim, and David Y Markevitch, and Jennifer Vela, and Adrian Ray, and Tomas Cihlar
May 2008, Yao xue xue bao = Acta pharmaceutica Sinica,
Richard L Mackman, and Constantine G Boojamra, and Vidya Prasad, and Lijun Zhang, and Kuei-Ying Lin, and Oleg Petrakovsky, and Darius Babusis, and James Chen, and Janet Douglas, and Deborah Grant, and Hon C Hui, and Choung U Kim, and David Y Markevitch, and Jennifer Vela, and Adrian Ray, and Tomas Cihlar
March 2019, ChemMedChem,
Copied contents to your clipboard!